FIELD: biotechnology.
SUBSTANCE: disclosed are an antibody or a fragment thereof which specifically bind to the KIR3DL3 protein, a fused polypeptide and a conjugate containing said antibody or a fragment thereof, compositions based thereon. Invention also relates to methods of using the antibodies for treating human diseases associated with high expression of the KIR3DL3 protein, including cancer.
EFFECT: invention provides neutralization of KIR3DL3-induced immune suppression.
45 cl, 27 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| THERAPEUTIC USE OF LONG-ACTING TRIPLE AGONIST CONJUGATE HAVING ACTIVITIES ON ALL GLUCAGON/GLP-1/GIP RECEPTORS FOR TREATING LUNG DISEASE | 2020 |
|
RU2829342C1 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
| CD40L-SPECIFIC FRAMEWORK STRUCTURES DERIVED FROM Tn3, AND METHODS OF USE THEREOF | 2012 |
|
RU2826189C2 |
